NCT06860230已完成不适用
Evaluation of NellcorTM Pulse Oximetry Accuracy With the Philips picoSAT X SpO2 Board With Fourier Artifact Suppression Technology in Adult Volunteers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Evaluation of Saturation Accuracy
研究概览
简要总结
Evaluation of Philips FAST technology with Nellcor sensors
详细描述
Evaluate saturation accuracy claims for the Philips picoSAT X SpO2 board with FAST algorithm, paired with Nellcor™ sensors in a diverse subject population, over a specified saturation range
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects ≥ 18 and < 51 years of age
- •Subject is willing and able to comply with study procedures and duration
- •Subject is willing to sign an informed consent
- •Subject weighs >40kg
- •Subject is a non-smoker or has not smoked within 36 hours prior to the study
- •Cleared same day health assessment form and health screening
排除标准
- •Subject is considered as being morbidly obese (defined as BMI >39.5)
- •Compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the sites utilized)
- •Participants of childbearing potential who are pregnant, who are trying to get pregnant, or who have a urine test positive for pregnancy on the day of the study
- •Subjects with COHb levels >3% as assessed by CO-Oximetry during the procedure
- •tHb < 10 g/dl as assessed by CO-Oximetry during the procedure
- •MetHb ≥ 2% as assessed by CO-Oximetry during the procedure
- •Subjects with known respiratory conditions such as:
- •uncontrolled / severe asthma
- •flu or influenza type infection
- •pneumonia / bronchitis
- •shortness of breath / respiratory distress
- •unresolved respiratory or lung surgery
- •emphysema, COPD, lung disease
- •recent COVID (last 2 months)
- •Subjects with known heart or cardiovascular conditions such as:
- •hypertension: systolic pressure >140mmHg, or diastolic pressure >90mmHg on 3 consecutive readings
- •previous cardiovascular surgery
- •chest pain (angina)
- •heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
- •previous heart attack
- •blocked artery
- •unexplained shortness of breath
- •congestive heart failure (CHF)
- •history of stroke
- •transient ischemic attack
- •carotid artery disease
- •myocardial ischemia
- •myocardial infarction
- •cardiomyopathy
- •implantable active medical device such as pacemaker or automatic defibrillator
- •Self-reported health conditions as identified in the Health Assessment Form
- •uncontrolled thyroid disease
- •kidney disease / chronic renal impairment
- •history of seizures (except childhood febrile seizures)
- •history of unexplained syncope
- •recent history of frequent migraine headaches
- •recent symptomatic head injury, within the last 2 months
- •cancer requiring chemotherapy, radiation, or current treatment
- •subjects with known clotting disorders
- •history of bleeding disorders or personal history of prolonged bleeding from injury
- •history of blood clots
- •sickle cell trait or disease
- •current use of blood thinner: prescription or daily use of aspirin
- •subjects with Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
- •participants with severe allergy to iodine (only applicable if iodine is used)
- •subjects with prior or known severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocain) or heparin
- •arterial cannulation within the last 30 days prior to study date, (this may exclude only one radial artery site, left or right)
- •history of clinically significant complications from previous arterial cannulation
- •Failure of Allen's test
- •unwillingness or inability to remove colored nail polish or colored artificial nails other than clear from test digits
- 另有 1 项未显示
结局指标
主要结局
Evaluation of Saturation Accuracy
时间窗: 2 - 3 hours
Performance will be determined by calculating the accuracy in terms of root mean square difference (ARMS) comparing the noninvasive oxygen saturation measurement (SpO2) to the arterial oxygen saturation (SaO2) value obtained from a reference blood sample.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin PigmentationHealthyNCT06148623Masimo Corporation70
已完成
不适用
Philps FAST2022 picoSAT Pulse Oximetry Desaturation StudySpO2 (Peripheral Oxygen Saturation) Measurement ValidationNCT05683366Philips Clinical & Medical Affairs Global72
已完成
不适用
SpO2 Validation Study - Philips FAST 2024Pulse OximetryNCT06484452Philips Clinical & Medical Affairs Global113
已完成
不适用
SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion ConditionsHypoxiaNCT02475668Nonin Medical, Inc13
已完成
不适用
Comparision evaluation of Puls oximetry, Electrical Pulp test and Cold Test for assessing pulp vitality in permanent immature vital teethPulp vitality of immature teeth.Other and unspecified diseases of pulp and periapical tissuesIRCT2016022326723N1Shahid Beheshti University of Medical Sciences120